Universitätsklinikum Hamburg-Eppendorf (UKE)

Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT (2020) Schmidt-Hieber M, Engelhard D, Ullmann A, Ljungman P, Maertens J, Martino R, Rovira M, et al. Journal article Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria (2020) Lim MS, Beyer T, Babayan A, Bergmann MM, Brehme M, Buyx A, Czernin J, et al. Journal article Dopamine Receptor Activation Modulates the Integrity of the Perisynaptic Extracellular Matrix at Excitatory Synapses (2020) Mitloehner J, Kaushik R, Niekisch H, Blondiaux A, Gee CE, Happel MFK, Gundelfinger E, et al. Journal article Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Feasibility and Satisfaction of Young Cancer Survivors Participating in Preventive Interventions. A Subgroup Analysis of the Care for CAYA Program (CFC-P) (2020) Elmers S, Beitzen-Heineke A, Von Grundherr J, Jensen W, Koch B, Mann J, Salchow J, et al. Conference contribution Health Problems and Quality of Life of Young Cancer Survivors in the Comprehensive Care for CAYA Program (2020) Elmers S, Beitzen-Heineke A, Von Grundherr J, Jensen W, Koch B, Mann J, Salchow J, et al. Conference contribution Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344) (2020) Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC) (2020) Friedl TWP, Krause S, Fasching P, Schneeweiss A, Mueller V, Riethdorf S, Taran FA, et al. Conference contribution Itching and Neurodermatitis: Results from the German Neurodermatitis Register TREATgermany (2020) Haufe E, Heinrich L, Weisshaar E, Abraham S, Heratizadeh A, Harder I, Kleinheinz A, et al. Conference contribution